ClinicalTrials.gg
CompletedNCT05874336Updated May 24, 2023

An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol

A Phase 1 interventional study of Aramchol in NASH, sponsored by Galmed Pharmaceuticals Ltd. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.
  • Registered 2 years 10 months after the study started (first participant enrolled Jun 2020, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
35 Years to 64 Years
Sex
Male
01

Study summary

A two-part open-label study to assess the absolute bioavailability of aramchol and the mass balance recovery, metabolite profile and identification of metabolite structures for [14C]-aramchol in healthy male subjects

Read the detailed description

A two-part open-label study to assess the absolute bioavailability of aramchol and the mass balance recovery, metabolite profile and identification of metabolite structures for [14C]-aramchol in healthy male subjects.

A subject was considered evaluable in Part 1 if they provided PK samples for up to a minimum of 120 h after first investigational medicinal product (IMP) administration. A subject was considered evaluable in Part 2 if they provided biological samples for up to a minimum of 144 h after IMP administration or demonstrated >90% mass balance recovery, or \<1% of the administered dose eliminated in excreta for 2 consecutive days, whichever was sooner.

02

Conditions studied

  • NASH
03

In context

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males
  2. Aged 35 to 64 years at the time of signing
  3. (BMI) of 18.0 to 35.0 kg/m2 as measured at screening
  4. Must be willing and able to communicate and participate in the whole study
  5. Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)
  6. Must provide written informed consent
  7. Must agree to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
  2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  3. History of any drug or alcohol abuse in the past 2 years
  4. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)
  5. A confirmed positive alcohol breath test at screening or each admission
  6. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or each admission
  7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  8. Subjects with pregnant or lactating partners
  9. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
  10. Participation in any study involving administration of any [14C]-labelled compound within 12 months prior to dosing in Part 1 of this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single dose administration of Aramchol in Part 1 and Part 2

    6 subjects received Aramchol in Part 1 and Part 2 of the study

    Drug: Aramchol

Interventions

  • Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.

    Also known as: Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid)

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability

    Measure the AUC(0-inf) of orally and intravenously (IV) administered Aramchol

    Time frame: 10 days

  2. Mass balance recovery

    Assess the mass balance recovery of total amounts of radioactivity excreted in urine and feces

    Time frame: 10 days

  3. Metabolite profiling

    Assess the potential metabolites of Aramchol and determine their chemical structure in plasma, urine and fecal samples

    Time frame: 10 days

Secondary outcomes

  1. Routes and rates of elimination

    Determine the routes and rates of elimination of \[14C\]-Aramchol in excreta

    Time frame: 10 days

  2. Chemical structure of each metabolite accounting for more than 10%

    Identify the chemical structure of each metabolite accounting for more than 10% by area under the curve (AUC) of circulating total radioactivity or 10% of the dose in urine and feces

    Time frame: 10 days

  3. PK- Area under the concentration-time curve (AUC)

    Investigate the plasma Area under the concentration-time curve (AUC) of Aramchol

    Time frame: 10 days

  4. PK- Time of maximum observed concentration (Tmax)

    Investigate the plasma Time of maximum observed concentration (Tmax) of Aramchol

    Time frame: 10 days

  5. PK- Maximum observed concentration (Cmax)

    Investigate the plasma Maximum observed concentration (Cmax) of Aramchol

    Time frame: 10 days

  6. PK- Total body clearance (CL)

    Investigate the Total body clearance (CL) of Aramchol

    Time frame: 10 days

  7. Safety- Adverse events

    Assess and characterize the number of participants with adverse events

    Time frame: 10 days

  8. Safety- Clinical laboratory parameters

    Assess and characterize the number of participants with clinically significant changes in clinical laboratory parameters

    Time frame: 10 days

07

Study locations

1 site
  • Quotient Sciences, Mere Way, Ruddington Fields, Ruddington, Nottingham, NG11 6JS, UK.
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Consideration will be made whether to share any data of this mass balance study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Aug 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 24, 2023
StartActual
Jun 17, 2020
Primary completionActual
Aug 11, 2020
CompletionActual
Aug 11, 2020
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05874336
Lead sponsor
Galmed Pharmaceuticals Ltd
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Jun 17, 2020
Primary completion
Aug 11, 2020
Completion
Aug 11, 2020
Last update
May 24, 2023

Study contacts

John Posner, PhD, FRCP
study director · Consultant

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion